• Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy organizations
• Research shows that sleep disorders are associated with increased risks of cardiovascular comorbidities, including those with narcolepsy being two- to three-times more likely to have a stroke or heart attack than people without narcolepsy

DUBLIN, March 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an expansion of its support of the American Heart Association (Association) to provide the sleep disorder community an in-depth understanding of the cardiovascular risks associated with these debilitating disorders. Through this initiative, the Association aims to help people living with sleep disorders determine when professional help may be appropriate and healthcare professionals recognize ways to improve heart health for the patients they treat.

An estimated 50 million to 70 million American adults have a chronic, or ongoing, sleep disorder.1 Studies have shown that poor sleep quality and duration can be associated with high blood pressure, elevated cholesterol, stroke and heart attacks.2

"With more than two decades of scientific research in complex and difficult-to-treat neurological conditions, we have long been at the forefront of pr…